EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selected Serum Biomarkers in Patients with Relapsing-Remitting Multiple Sclerosis—A 3-Year Prospective Pilot Study

Przemyslaw Puz iD, Katarzyna Maciejowska, Daria Gendosz de Carrillo, Malgorzata Janik iD, Anetta Lasek-Bal iD

Medical Sciences · 2025

DOI: 10.3390/medsci13040283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Sciences, 2025. Verfasst von Przemyslaw Puz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Osteopontin, Occludin, Neurofilament Proteins. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this study was to evaluate the significance of serum concentrations of the inflammatory marker osteopontin, the blood–brain barrier damage marker occludin, and the neurodegeneration marker neurofilament light chain (NFL) in patients with relapsing-remitting multiple sclerosis (RRMS) for predicting disease activity and progression.

Methods

This prospective cohort study enrolled 150 patients with RRMS. Initial serum levels of NFL, occludin, and osteopontin were compared between patients who met or did not meet the no evidence of disease activity (NEDA) criteria and its components (relapses, magnetic resonance imaging activity, and Expanded Disability Status Scale progression) within 36 months of observation. Independent factors affecting study outcomes at month 36 were identified from baseline data, including age, gender, initial prognostic profile, and serum levels of NFL, occludin, and osteopontin, as well as treatment type.

Results

We found lower osteopontin concentrations in patients receiving highly effective treatment compared with those receiving platform therapies (13.64 ± 5.41 ng/mL, CI 11.75–15.53 vs. 17.33 ± 8.00 ng/mL, CI 15.66–18.61; p = 0.03). There was a significant correlation between NFL levels and patient age (Spearman’s rho = 0.3045, p = 0.0002) and between NFL levels and disease duration (Spearman’s rho = 0.1945, p = 0.02). NEDA during the 3-year observation period was achieved by 58 (38.67%) patients. Patients with NEDA showed significantly lower serum concentrations of occludin, NFL, and osteopontin than those without NEDA.

Conclusions

Serum levels of NFL, osteopontin, and occludin may serve as biomarkers of disease activity in patients with RRMS. The clinical relevance of these biomarkers should be confirmed through repeated serum marker assessments in MS patients and validation studies involving larger sample sizes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingOsteopontinOccludinNeurofilament ProteinsBiomarkersProspective StudiesRecurrenceDisease ProgressionDisability EvaluationMagnetic Resonance ImagingPilot ProjectsFollow-Up StudiesHumansMaleFemaleYoung AdultAdultMiddle Aged

Stichwörter der Autor:innen

biomarkersmultiple sclerosisneurofilament light chainoccludinosteopontin

Substanzen

BiomarkersSPP1 protein, humanOsteopontinOCLN protein, humanOccludinneurofilament protein LNeurofilament Proteins

Autor:innen und Institutionen

  • Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.
  • Department of Physiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40-752 Katowice, Poland.
  • Department of Histology and Cell Pathology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 41-808 Zabrze, Poland.
  • Faculty of Science and Technology, Institute of Biomedical Engineering, University of Silesia in Katowice, 41-200 Sosnowiec, Poland.

ORCID-Profile: Przemyslaw Puz, Malgorzata Janik, Anetta Lasek-Bal

Förderung

  • Medical University of Silesia

Zitieren

APA

Puz, P., Maciejowska, K., Gendosz de Carrillo, D., Janik, M., & Lasek-Bal, A. (2025). Selected Serum Biomarkers in Patients with Relapsing-Remitting Multiple Sclerosis—A 3-Year Prospective Pilot Study. Medical Sciences. https://doi.org/10.3390/medsci13040283

Vancouver

Puz P, Maciejowska K, Gendosz de Carrillo D, Janik M, Lasek-Bal A. Selected Serum Biomarkers in Patients with Relapsing-Remitting Multiple Sclerosis—A 3-Year Prospective Pilot Study. Medical Sciences. 2025. doi:10.3390/medsci13040283

BibTeX
@article{Puz2025,
  author = {Puz, Przemyslaw and Maciejowska, Katarzyna and Gendosz de Carrillo, Daria and Janik, Malgorzata and Lasek-Bal, Anetta},
  title = {Selected Serum Biomarkers in Patients with Relapsing-Remitting Multiple Sclerosis—A 3-Year Prospective Pilot Study},
  journal = {Medical Sciences},
  year = {2025},
  doi = {10.3390/medsci13040283}
}
Kostenlos starten →